![Cureus | Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media Cureus | Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media](https://assets.cureus.com/uploads/figure/file/42140/lightbox_258891d092a011e8ae632f36251f9cc2-Figure-4.png)
Cureus | Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media
![Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone](https://neurologyindia.com/articles/2017/65/4/images/ni_2017_65_4_746_209533_t3.jpg)
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone
![Frontiers | Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease Frontiers | Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease](https://www.frontiersin.org/files/Articles/355629/fneur-09-00260-HTML/image_m/fneur-09-00260-t001.jpg)
Frontiers | Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease
![Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD - MDS Abstracts Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2018/08/0120_0189_000645_MCID.png)
Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD - MDS Abstracts
![Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media - Cureus Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media - Cureus](https://assets.cureus.com/uploads/figure/file/42143/644d7d3092a111e8a3aa03bb85c7f9a2-Figure-7.png)
Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials | Media - Cureus
![Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort | SpringerLink Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00415-019-09348-3/MediaObjects/415_2019_9348_Fig1_HTML.png)
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort | SpringerLink
![Frontiers | Mild Motor Signs Matter in Typical Brain Aging: The Value of the UPDRS Score Within a Functionally Intact Cohort of Older Adults Frontiers | Mild Motor Signs Matter in Typical Brain Aging: The Value of the UPDRS Score Within a Functionally Intact Cohort of Older Adults](https://www.frontiersin.org/files/Articles/594637/fnagi-13-594637-HTML/image_m/fnagi-13-594637-t001.jpg)
Frontiers | Mild Motor Signs Matter in Typical Brain Aging: The Value of the UPDRS Score Within a Functionally Intact Cohort of Older Adults
Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home
![PDF] The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function. | Semantic Scholar PDF] The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5b7dbe630511e0af5e2e8fb44b09a46a3e64cd7c/4-Table3-1.png)
PDF] The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function. | Semantic Scholar
![Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone](https://neurologyindia.com/articles/2017/65/4/images/ni_2017_65_4_746_209533_t1.jpg)
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone
![Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts - The Lancet Neurology Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts - The Lancet Neurology](https://www.thelancet.com/cms/attachment/4fdb2f29-89cf-4c0e-b751-651ee2b4dee5/gr1_lrg.jpg)